What is Tirzepatide?
Tirzepatide (Mounjaro for T2D, Zepbound for obesity) is Eli Lilly's FDA-approved dual GLP-1/GIP receptor agonist and the first approved twincretin therapy. SURMOUNT-1 trial demonstrated up to 22.5% average body weight reduction at 72 weeks with 15mg — the highest efficacy among approved obesity medications at time of approval. Also approved for obstructive sleep apnea reduction (2024).
Mechanism of Action
Dual GLP-1 receptor and GIP receptor co-agonism; combined incretin effect enhances insulin sensitivity via GIPR, amplifies appetite suppression via GLP1R, and accelerates fat oxidation and energy expenditure beyond GLP-1 alone
Target: GLP-1 receptor (GLP1R) & GIP receptor (GIPR)
Educational reference — not medical advice. Educational research index only — not medical advice. Literature maturity is not a verdict on whether a compound works in people. Community reports are not evidence of efficacy.
Evidence at a glance
Derived · maturity-1.0Human efficacy is unproven unless an approved label or completed published efficacy program says otherwise. Counts reflect indexed literature volume/kind — never a verdict on effect.
Literature maturity
established 90/100
PubMed hits
2,489
CT.gov trials
298
Strong-human apps
3
Sample papers
8
Sample articles by era
- pre-20182
- 2018-20201
- 2021-20236
- 2024-202616
Application grades (curated)
- Human-grade apps4
- Animal / in-vitro0
- Mechanistic0
Does literature support studied applications?
Grades reflect cited literature posture — not a treatment recommendation. Community notes are never efficacy evidence.
| Application | Cited evidence | Grade | Community |
|---|---|---|---|
| Type 2 diabetes mellitus (glycemic control) | SURPASS phase 3 program supports weekly tirzepatide for HbA1c reduction as an approved indication. | Strong human | Community reports vary; not evidence of efficacy. |
| Chronic weight management | SURMOUNT phase 3 program supports substantial mean weight reduction at approved doses. | Strong human | Community reports vary; not evidence of efficacy. |
| Obstructive sleep apnea in adults with obesity | SURMOUNT-OSA evaluated tirzepatide in moderate-to-severe OSA with obesity. | Strong human | Community reports vary; not evidence of efficacy. |
| Cardiovascular / HFpEF outcomes (investigational endpoints) | Outcomes data continue to emerge; not treated here as a broad CV efficacy claim. | Limited human | Community reports vary; not evidence of efficacy. |
Pharmacology
Mechanism of action
- •Dual GLP-1 receptor and GIP receptor co-agonism; combined incretin effect enhances insulin sensitivity via GIPR, amplifies appetite suppression via GLP1R, and accelerates fat oxidation and energy expenditure beyond GLP-1 alone
- •Primary target framing: GLP-1 receptor (GLP1R) & GIP receptor (GIPR)
Half-life
5 days
Identity & chemistry
- CAS
- 2023788-19-2
- PubChem
- CID 166567236
- Formula
- C225H348N48O68
- Molar mass
- 4813 Da
- InChIKey
- BTSOGEDATSQOAF-MCNPHUAVSA-N
Identity cross-checked with PubChem where available. Compass HTML used only as a bootstrap checklist — not republished as product copy.
Storage & stability
- Lyophilized
- 2–8°C; lyophilized typical shelf 18–24 months
- Reconstituted
- 2–8°C; in-use window often 28–56 days (product-dependent)
- Tell-tale degradation
- !Cloudiness, clumping, or particles after mixing
- !Discoloration versus the expected clear/colorless (or labeled) solution
- !Failed or incomplete reconstitution of lyophilized cake
Educational estimates. Prefer product labeling and peptide shelf-life tool.
Lab handling posture
Research / educational handling notes only. Not a substitute for an SDS.
- •Use PPE appropriate for peptide powder/solution handling
- •Avoid inhalation of lyophilized powder; handle spills per institutional policy
- •Do not present research materials as medicines
Sample indexed literature
- Tirzepatide did not impact metabolic adaptation in people with obesity, but increased fat oxidation.
Cell metabolism · 2025 · PMID 40203836
- Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity: The SURMOUNT-4 Randomized Clinical Trial.
JAMA · 2024 · PMID 38078870
- Tirzepatide as a Potential Disease-Modifying Therapy in Lipedema: A Narrative Review on Bridging Metabolism, Inflammation, and Fibrosis.
International journal of molecular sciences · 2025 · PMID 41226777
- Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes.
The New England journal of medicine · 2021 · PMID 34170647
- Tirzepatide as Compared with Semaglutide for the Treatment of Obesity.
The New England journal of medicine · 2025 · PMID 40353578
- Tirzepatide: A Systematic Update.
International journal of molecular sciences · 2022 · PMID 36498958
Research Indications
Clinical trials demonstrate significant body weight reduction with sustained benefit
Improves glycemic control and A1C levels in type 2 diabetes
Associated with reduced cardiovascular events in high-risk patients
Addresses multiple components of metabolic syndrome simultaneously
Research Protocols
These are commonly discussed research protocols — not medical advice. Consult a healthcare provider before use.
| Goal | Dose | Frequency | Route |
|---|---|---|---|
| Starting Dose (Week 1–4) | 2.5 mg | Once weekly | Subcutaneous injection |
| Escalation (Week 5–8) | 5 mg | Once weekly | Subcutaneous injection |
| Moderate Dose (Week 9–12) | 7.5 mg | Once weekly | Subcutaneous injection |
| Maximum Dose | 15 mg | Once weekly | Subcutaneous injection |
Peptide & Drug Interactions
Always consult your healthcare provider before combining with other compounds. Use our Interaction Checker for reference.
How to Reconstitute & Inject
Use bacteriostatic (BAC) water only. Avoid saline — may cause precipitation. Refrigerate and use within 28 days.
- 1
Remove Tirzepatide vial from refrigeration and allow to reach room temperature (15–20 minutes)
- 2
Clean vial top with alcohol swab and allow to air dry completely
- 3
Using a sterile syringe, draw the calculated volume of bacteriostatic water (BAC water)
- 4
Inject BAC water slowly down the side of the vial — do not aim directly at the powder
- 5
Gently swirl in circular motions — DO NOT shake vigorously as this degrades the peptide
- 6
Allow 2–3 minutes for full dissolution — solution should be clear and colorless
- 7
Draw calculated dose into an insulin syringe for subcutaneous injection
- 8
Inject into abdomen, thigh, or upper arm. Rotate injection sites to prevent lipodystrophy
- 9
Store reconstituted solution refrigerated (2–8°C) and use within 28 days
What to Expect
Week 1–2
Initial appetite suppression may begin. Mild GI effects (nausea, fullness) as your body adapts.
Week 2–4
Noticeable reduction in food cravings and portion sizes. Early weight changes begin.
Week 4–8
Significant appetite control and steady weight loss. Improved blood sugar if applicable.
Week 8–16
Substantial weight reduction and enhanced energy. Metabolic markers begin improving.
Week 16–24
Major weight loss milestone with cardiovascular benefits and improved lipid profiles.
Week 24+
Maximum clinical efficacy. Comprehensive metabolic improvements and sustained benefits.
Side Effects & Safety
- Nausea (most common, typically dose-dependent and transient)
- Diarrhea or constipation during dose escalation
- Vomiting, especially when starting or increasing dose
- Reduced appetite and early satiety
- Injection site reactions (redness, bruising)
- Fatigue, particularly in early weeks
- Rare: Pancreatitis — discontinue immediately with severe abdominal pain
- Rare: Thyroid C-cell effects (contraindicated with MEN2 or thyroid cancer history)
FDA Status & Regulatory Info
Tirzepatide (Mounjaro for T2D, Zepbound for obesity) is Eli Lilly's FDA-approved dual GLP-1/GIP receptor agonist and the first approved twincretin therapy. SURMOUNT-1 trial demonstrated up to 22.5% average body weight reduction at 72 weeks with 15mg — the highest efficacy among approved obesity medications at time of approval. Also approved for obstructive sleep apnea reduction (2024).
Frequently Asked Questions
Research References
External links for education only. We do not control third-party content.
Community-reported data
The information below reflects self-reported experiences from PeptIQ app users. It is not clinical evidence and should not replace professional medical advice.
Community Intelligence
What 7 users report
Overall experience
From check-in ratings — separate from side effects logged below. Side effects are logged separately from overall experience. A favorable check-in can still include nausea, fatigue, or injection-site reactions.
Favorable 14% · Mixed 0% · Unfavorable overall 86%
Most reported benefits
Benefits users selected when logging a favorable or mixed check-in.
Most logged side effects
Side effects are logged separately from overall experience. A favorable check-in can still include nausea, fatigue, or injection-site reactions.
Self-reported dose per injection
Median bucket: 5+ mg · Most common: 5+ mg
Reports span 0.4 to ≥ 5 mg (open-ended top bucket)
Anonymized self-reports from PeptIQ users — not prescribing guidance. Buckets group similar logged amounts; open-ended top buckets mean “at least” that dose.
Share Your Experience
Rate Tirzepatide in the PeptIQ app and help the community make informed decisions.
Educational information only
This page is for educational reference. It is not medical or legal advice. PeptIQ does not sell peptides or list vendors. Consult the FDA and a licensed healthcare professional for current regulations and individualized guidance.